Mentari Therapeutics
Mentari Therapeutics is developing a portfolio of targeted biologics for migraine, focusing on the newly validated PACAP pathway distinct from existing CGRP-based therapies. Its lead programs include MT-001, an anti-PACAP antibody, and MT-002, a bispecific antibody blocking both CGRP and PACAP simultaneously. The company aims to deliver better outcomes for the majority of migraine sufferers who do not achieve adequate relief with current treatments.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$200MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Anti-CGRP therapies marked a turning point in migraine care, but significant unmet need remains, with an estimated 40-50% of patients on these treatments failing to achieve a 50% or greater reduction in monthly migraine days. Migraine affects more than 1 billion people globally, yet many patients continue to experience frequent and debilitating attacks despite available treatments.
Solution
Mentari Therapeutics is developing a portfolio of next-generation biologics targeting validated pathways in migraine biology, with lead programs focused on PACAP—a pathway distinct from CGRP signaling. MT-001 is an investigational anti-PACAP monoclonal antibody designed to block PACAP with potential for best-in-class efficacy. MT-002 is a bispecific antibody designed to block both PACAP and CGRP simultaneously, with the potential to deliver greater efficacy than targeting either pathway alone. Both programs incorporate clinically validated half-life extension modifications to support convenient, infrequent subcutaneous dosing. The broader pipeline includes five programs targeting key migraine pathways, including additional bispecifics and monoclonal antibodies.
Target Audience
Primary audience is people living with migraine who have inadequate relief from existing anti-CGRP therapies, along with the neurologists and headache specialists who treat them.
Features
- MT-001: investigational anti-PACAP monoclonal antibody with effector-null IgG1 Fc and half-life extension modification for infrequent subcutaneous dosing
- MT-002: bispecific antibody in a 1+1 IgG-like format combining validated CGRP-binding with potent PACAP inhibition, designed for monoclonal antibody-like pharmacokinetics
- Dual-pathway inhibition approach targeting both PACAP and CGRP to potentially achieve superior efficacy versus monotherapy
- Pipeline of five programs including bispecific and monoclonal antibodies targeting validated migraine pathways
- Half-life extension technology incorporated across lead programs to reduce treatment burden through convenient dosing